NFKB1 and breast cancer: Li et al demonstrated that MEF2D, a member of the MEF2 family, could directly target the IKBKE promoter to control its translation to enhance tumor chemotherapeutic resistance in ovarian carcinoma.86 Cheng et al87 demonstrated that zinc finger protein (ZNF382), which functioned as a tumor suppressor, was methylated in multiple primary tumors, including nasopharyngeal, esophageal, colon, gastric, and breast cancers, thereby suppressing the NF‐κB pathway and AP‐1 signaling through downregulating IKBKE.